Matching Geography

Reports matching your search in:
 
 

Research Assistance

 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!
 

Blood Diseases

1594

There are several types of blood related diseases requiring a variety of therapeutics. Agnogenic myeloid Metaplasia also known as (AMM) takes place in people when the bone marrow becomes scarred. This condition makes the bone marrow to reduce the manufacture of blood cells

When the bone marrow produces too much blood cell, the result is Polycythemia Vera; this is however a condition that is not common.

Polycythemia Vera is a result of a high concentration of red blood cells only, though additional white blood cells and blood platelets are also being produced. Sepsis also known as the Systemic inflammatory response syndrome (SIRS) is a life threatening condition. This is a bacterial infection, infecting the blood stream of the patient.

When hemoglobin of the type A becomes infected they turn into a kind of peculiar shape. This is the shape of a sickle and hence the name sickle cell anemia. Hyperglycemia is condition wherein the sugar in blood increases to level more than the normal. Hyperglycemia is considered generally as the initial signal of diabetes mellitus. Leukemia : is cancer of the blood-forming tissues characterized by a large increase in the numbers of white blood cells (leukocytes) in the circulation or bone marrow is Leukemia. When in leukemia, white blood cells are produced in the bone marrow and lymph system is immature and abnormal. A variety of market research reports contain information on the diseases, patient statistics and therapeutics used to treat them. Several companies are actively involved in the blood disorders market.

RSS Feeds

All reports in Blood Diseases

< prev 1  2  3  4  next >
Chemotherapy Induced Anemia – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... the therapeutic development for Chemotherapy Induced Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia. 'Chemotherapy Induced ...  |  more...
$500.00
Hemophilia A – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... for Hemophilia A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia A. 'Hemophilia A - Pipeline Review, H1 2012' ...  |  more...
$500.00
Hemophilia – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. 'Hemophilia - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Anemia – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. 'Anemia - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Hemophilia B – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... for Hemophilia B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia B. 'Hemophilia B - Pipeline Review, H1 2012' ...  |  more...
$500.00
Anemia Global Clinical Trials Review, H1, 2012
1/27/2012 | published by: GlobalData
... to the clinical trials on Anemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of ...  |  more...
$1,000.00
Global Intravenous (IV) Iron Drugs Market: 2011 Edition
1/1/2012 | published by: Koncept Analytics
... energy. Decline in iron can therefore lead to certain major problems. Although oral iron supplements can be used to maintain the iron levels in the body, but oral supplements are chronic treatments and generally have ...  |  more...
$800.00
Hemophilia Global Clinical Trials Review, H2, 2011
11/15/2011 | published by: GlobalData
... to the clinical trials on Hemophilia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of ...  |  more...
$1,000.00
Future Technology Trends and Upcoming Players in Hemophilia Therapeutics Market
10/31/2011 | published by: GlobalData
... essential source of information and analysis on Hemophilia Therapeutics Market. The report provides insights on the upcoming molecules in the hemophilia therapeutics maket. Most importantly, the report provides valuable insights on the disease burden and ...  |  more...
$500.00
Chemotherapy Induced Anemia - Pipeline Review, H2 2011
10/26/2011 | published by: Global Markets Direct
... the therapeutic development for Chemotherapy Induced Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia. 'Chemotherapy Induced ...  |  more...
$500.00
Hemophilia A Global Clinical Trials Review, H2, 2011
10/22/2011 | published by: GlobalData
... and data relating to the clinical trials on Hemophilia A. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...  |  more...
$1,000.00
Hemophilia - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. 'Hemophilia - Pipeline Review, H2 2011' is built using data and information ...  |  more...
$500.00
Hemophilia B - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... for Hemophilia B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia B. 'Hemophilia B - Pipeline Review, H2 2011' ...  |  more...
$500.00
Anemia - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. 'Anemia - Pipeline Review, H2 2011' is built using data and information ...  |  more...
$500.00
Hemophilia A - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... for Hemophilia A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia A. 'Hemophilia A - Pipeline Review, H2 2011' ...  |  more...
$500.00
Blood, Organ & Ambulatory Health Services in the US - Industry Risk Rating Report
9/26/2011 | published by: IBISWorld
... Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Blood, Organ & Ambulatory Health Services in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business ...  |  more...
$910.00
Bleeding and Clotting Disorders Global Clinical Trials Review, H2, 2011
9/21/2011 | published by: GlobalData
... scenario. This report provides elemental information and data relating to the clinical trials on Bleeding and Clotting Disorders. It includes an overview of the trial numbers and their recruitment status as per the site of ...  |  more...
$1,000.00
Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth
9/17/2011 | published by: GBI Research
... Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth”. The report provides in-depth analysis of drivers and barriers that impact the global blood disorders market. The ...  |  more...
$3,500.00
Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline
9/17/2011 | published by: GBI Research
... its latest research, “Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline”, provides in-depth analysis of unmet needs, drivers ...  |  more...
$3,500.00
Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
9/12/2011 | published by: GlobalData
... essential source of information and analysis on the global Hemophilia Therapeutics market. The report identifies the key trends shaping and driving the global Hemophilia Therapeutics market. The report also provides insights on the prevalent competitive ...  |  more...
$3,500.00
Special Report: Do Emerging Therapies Offer Better Treatment Options for Hemophilia Patients?
9/1/2011 | published by: Decision Resources
... disease is treated by giving intravenous transfusions of the deficient factor, but a strong need remains for the development of new factors that would eliminate or reduce inhibitor production against the factor replacement therapy. Interviewed ...  |  more...
$9,200.00
Iron Deficiency Anemia - Pipeline Review, H2 2011
8/31/2011 | published by: Global Markets Direct
... the therapeutic development for Iron Deficiency Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Iron Deficiency Anemia. 'Iron Deficiency ...  |  more...
$500.00
Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
8/31/2011 | published by: GlobalData
... essential source of information and analysis on the global Anemia Therapeutics market. The report identifies the key trends shaping and driving the global Anemia Therapeutics market. The report also provides insights on the prevalent competitive ...  |  more...
$3,500.00
Hemophilia B Global Clinical Trials Review, H2, 2011
8/31/2011 | published by: GlobalData
... and data relating to the clinical trials on Hemophilia B. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ...  |  more...
$1,000.00
Erythropoiesis-Stimulating Agents in the Treatment of Chemotherapy Induced Anemia and Anemia in Chronic Kidney Disease in the US
8/18/2011 | published by: GlobalData
... Disease in the US“ provide key features of the Erythropoiesis-Stimulating Agents in the Treatment of Anemia Scope The scope of the report includes - Advantage of Erythropoiesis-Stimulating Agents in the Treatment of Anemia Reasons to ...  |  more...
$500.00
< prev 1  2  3  4  next >